Implementing and Evaluating a Data-to-Care Rx Strategy | RFA PS 21 004

Opportunity Information: Apply for RFA PS 21 004

Implementing and Evaluating a Data-to-Care Rx Strategy (RFA PS 21 004) is a CDC cooperative agreement funding opportunity under the U.S. Department of Health and Human Services that focuses on improving HIV treatment outcomes by using near real-time prescription information as a public health action tool. The central idea is to treat delayed or missed antiretroviral (ARV) prescription refills as an early warning signal that someone living with HIV may be slipping off therapy or disengaging from care, then respond quickly with tailored interventions that support adherence and re-engagement. The overall objectives are to increase HIV viral suppression, improve adherence to ARV therapy, and strengthen retention in ongoing HIV care.

The NOFO has three tightly connected purposes. First, recipients are expected to use real-time (or close to real-time) prescription data to identify people with HIV who are late filling ARV prescriptions, and then target those individuals for progressively intensive adherence and retention interventions. That progressive approach implies a stepped response rather than a one-size-fits-all model, typically starting with lower-burden outreach or reminders and escalating to more hands-on navigation, case management, or clinical linkage support if delays continue. Second, the program aims to figure out and document the essential steps and critical elements required to run a Data-to-Care Rx (D2C Rx) strategy effectively, including the practical workflows, partnerships, data handling processes, and decision points that make the approach work in the real world. Third, recipients must develop a D2C Rx implementation protocol along with supporting implementation materials so the strategy can be replicated, scaled, and adopted by other jurisdictions or organizations.

This opportunity is categorized as discretionary funding and uses a cooperative agreement mechanism, which generally means the CDC expects to have substantial involvement during the project period, such as collaborating on strategy development, evaluation design, and dissemination of lessons learned. It sits within the health funding activity category and is associated with CFDA numbers 93.941 and 93.943. The maximum award amount listed is $595,333, and the CDC anticipated making three awards, indicating a small, competitive cohort intended to test and refine the model in a limited number of settings before broader rollout.

Eligibility is broad and includes multiple levels of government (state, county, city or township, and special district governments), independent school districts, public and private institutions of higher education, federally recognized tribal governments and other tribal organizations, public housing authorities/Indian housing authorities, nonprofits with or without 501(c)(3) status (excluding higher education institutions in those categories), for-profit organizations other than small businesses, and small businesses. This wide eligibility suggests the CDC was open to a range of entities that can access prescription data through partnerships and can coordinate adherence and retention interventions, including health departments, academic partners, community-based organizations, and private-sector implementers.

Administratively, the opportunity was posted on September 30, 2020, with an application deadline of January 5, 2021, and electronic submissions due by 5:00 p.m. Eastern Time on the closing date. In practical terms, the work supported by this NOFO centers on building or enhancing the capability to ingest and act on prescription fill information quickly, translating that data into prioritized outreach lists, ensuring appropriate privacy and data-sharing arrangements, coordinating with clinical and community partners to contact individuals in a supportive way, and evaluating both outcomes (like viral suppression and retention in care) and implementation factors (like feasibility, timeliness, staffing needs, and the specific workflow steps that are most critical). The end product is not only improved patient outcomes in the funded sites, but also a clearer, standardized playbook for implementing D2C Rx strategies elsewhere.

• The Department of Health and Human Services, Centers for Disease Control and Prevention - ERA in the health sector is offering a public funding opportunity titled "Implementing and Evaluating a Data-to-Care Rx Strategy" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.941, 93.943.
• This funding opportunity was created on Sep 30, 2020.
• Applicants must submit their applications by Jan 05, 2021 Electronically submitted applications must be submitted no later than 500 p.m., ET, on the listed application due date.. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $595,333.00 in funding.
• The number of recipients for this funding is limited to 3 candidate(s).
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses.

Apply for RFA PS 21 004

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: